Search

Your search keyword '"Ozyilkan O"' showing total 202 results
Start Over Author "Ozyilkan O"
202 results on '"Ozyilkan O"'

1. Prognostic Usefulness Of Advanced Lung Cancer Inflammation Index In Locally-Advanced Pancreatic Carcinoma Patients Treated With Radical Chemoradiotherapy

Author

Topkan E, Mertsoylu H, Ozdemir Y, Sezer A, Kucuk A, Besen AA, Ozyilkan O, and Selek U

Subjects
Locally-advanced pancreas cancer, advanced lung cancer inflammation index, concurrent chemoradiotherapy, prognosis, survival outcomes, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Erkan Topkan,1 Huseyin Mertsoylu,2 Yurday Ozdemir,1 Ahmet Sezer,2 Ahmet Kucuk,3 Ali Ayberk Besen,2 Ozgur Ozyilkan,2 Ugur Selek4,5 1Department of Radiation Oncology, Baskent University Medical Faculty, Adana, Turkey; 2Department of Medical Oncology, Baskent University Medical Faculty, Adana, Turkey; 3Department of Radiation Oncology, Mersin City Hospital, Mersin, Turkey; 4Department of Radiation Oncology, Koc University School of Medicine, Istanbul, Turkey; 5Department of Radiation Oncology, The University of Texas, MD Anderson Cancer Center, Houston, TX, USACorrespondence: Erkan TopkanDepartment of Radiation Oncology, Baskent University Medical Faculty, Adana 01120, TurkeyTel +90-533-7381069Fax +90-322-3444452Email docdretopkan@gmail.comBackground/Aims: Previously advanced lung cancer inflammation index (ALI) has been demonstrated to have prognostic utility in the stratification of patients into distinctive survival groups, but the prognostic value of ALI has never been explored in the setting of locally advanced pancreatic carcinomas (LAPC) treated with concurrent chemoradiotherapy (CCRT). Hence, we aimed to investigate the prognostic value of pre-treatment ALI in LAPC patients who underwent radical CCRT.Methods: Present retrospective cohort analysis incorporated 141 LAPC patients who received radical CCRT. Accessibility of baseline ALI cutoff(s) impacting survival outcomes was sought by receiver operating characteristic (ROC) curve analysis. Interaction between the ALI and overall- (OS) and progression-free survival (PFS) comprised our primary and secondary endpoints, respectively.Results: At a median follow-up of 14.4 months (range: 3.2–74.2), the median PFS and OS were 7.5 (%95 CI: 5.9–9.1) and 14.6 months (%95 CI: 11.6–17.6), respectively. ROC curve analyses set the ideal ALI cutoff value at 25.3 (AUC: 75.6%; sensitivity: 72.7%; specificity: 70.3%) that exhibited significant associations with both the OS and PFS results. Patient stratification into two groups per ALI [≤25.3 (N=75) versus>25.3 (N=66)] showed that the ALI>25.3 group had significantly superior median OS (25.8 versus 11.4 months; P90 U/mL; P

Published
2019

2. Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication

Author

Bachelot, T., Bouzid, K., Campone, M., Desmoulins, I., Coudert, B., Bondarenko, I., Nowecki, Z., Glogowska, I., Ciruelos Gil, E., Errihani, H., Dalenc, F., Ricci, F., Dieras, V., Kaufman, B., Paluch-Shimon, S., Wardley, A., Schneeweiss, A., Ferreira, A., Mano, M., Kalofonos, H., Andreetta, C., Puglisi, F., Montemurro, F., Barrett, S., Zhang, Q., Mavroudis, D., Matus, J., Villarreal Garza, C., Beato, C., Ismael, G., Hu, X., Abdel Azeem, H., Gaafar, R., Perrin, C., Kerbrat, P., Ettl, J., Paepke, S., Hitre, E., Lang, I., Trudeau, M., Verma, S., Li, H., Hoffmann, O., Aktas, B., Cariello, A., Cruciani, G., Tienghi, A., Tondini, C., Al-Twegieri, T., Loman, N., Laing, R., Miles, D., Brain, E., Fasching, P., Lux, M., Frassoldati, A., Aziz, Z., Salas, J., Streb, J., Krzemieniecki, K., Wronski, A., Garcia Garcia, J., Menjon Beltran, S., Cicin, I., Schmid, P., Gallagher, C., Turner, N., Tong, Z., Boer, K., Juhász, B., Horvath, Z., Bianchini, G., Gianni, L., Curigliano, G., Juarez Ramiro, A., Susnjar, S., Matos, E., Sevillano, E., Garcia Estevez, L., Gokmen, E., Uslu, R., Wildiers, H., Schutz, F., Cruz, M., Bourgeois, H., von Schumann, R., Stemmer, S., Dominguez, A., Morales-Vásques, F., Wojtukiewicz, M., Trifunovic, J., Echarri Gonzalez, M.J., Illarramendi Mañas, J., Martinez De Dueñas, E., Voitko, N., Hicks, J., Waters, S., Barrett-Lee, P., Wheatley, D., De Boer, R., Cocquyt, V., Jerusalem, G., Barrios, C., Panasci, L., Mattson, J., Tanner, M., Gozy, M., Vasilopoulos, G., Papandreou, C., Revesz, J., Battelli, N., Benedetti, G., Latini, L., Gridelli, C., Lazaro Leon, J., Alarcón Company, J., Arance Fernandez, A., Barnadas Molins, A., Calvo Plaza, I., Bratos, R., Gonzalez Martin, A., Izarzugaza Peron, Y., Klint, L., Kovalev, A., McCarthy, N., Yeo, B., Kee, D., Thomson, J., White, S., Greil, R., Wang, S., Artignan, X., Juhasz-Böess, I., Rody, A., Ngan, R., Dourleshter, F., Goldberg, H., Doni, L., Di Costanzo, F., Ferraù, F., Drobniene, M., Aleknavicius, E., Rashid, K., Costa, L., de la Cruz Merino, L., Garcia Saenz, J., López, R., Del Val Munoz, O., Ozyilkan, O., Azribi, F., Jaafar, H., Baird, R., Verrill, M., Beith, J., Petzer, A., Moreira de Andrade, J., Bernstein, V., Macpherson, N., Rayson, D., Saad Eldin, I., Achille, M., Augereau, P., Müller, V., Rasco, A., Evron, E., Katz, D., Berardi, R., Cascinu, S., De Censi, A., Gennari, A., El-Saghir, N., Ghosn, M., Oosterkamp, H.M., Van den Bosch, J., Kukulska, M., Kalinka, E., Alonso, J., Dalmau Portulas, E., Del Mar Gordon Santiago, M., Pelaez Fernandez, I., Aksoy, S., Altundag, K., Senol Coskun, H., Bozcuk, H., Shparyk, Y., Barraclough, L., Levitt, N., Panwar, U., Kelly, S., Rigg, A., Varughese, M., Castillo, C., Fein, L., Malik, L., Stuart-Harris, R., Singer, C., Stoeger, H., Samonigg, H., Feng, J., Cedeño, M., Ruohola, J., Berdah, J.-F., Goncalves, A., Orfeuvre, H., Grischke, E.-M., Simon, E., Wagner, S., Koumakis, G., Papazisis, K., Ben Baruch, N., Fried, G., Geffen, D., Karminsky, N., Peretz, T., Cavanna, L., Pedrazzioli, P., Grasso, D., Ruggeri, E., D’Auria, G., Moscetti, L., Juozaityte, E., Rodriguez Cid, J., Roerdink, H., Siddiqi, N., Passos Coelho, J., Arcediano Del Amo, A., Garcia Garre, E., García Gonzalez, M., Garcia-Palomo Perez, A., Herenandez Perez, C., Lopez Alvarez, P., Lopez De Ceballos, M.H., Martínez Jañez, N., Mele Olive, M., McAdam, K., Perren, T., Dunn, G., Humphreys, A., Taylor, W., Vera, R., Kaen, L., Andel, J., Steger, G., De Grève, J., Huizing, M., Hegg, R., Joy, A., Kuruvilla, P., Sehdev, S., Smiljanic, S., Kütner, R., Alexandre, J., Grosjean, J., Laplaige, P., Largillier, R., Maes, P., Martin, P., Pottier, V., Christensen, B., Khandan, F., Lück, H.-J., Zahm, D.-M., Fountzilas, G., Karavasilis, V., Safra, T., Inbar, M., Ryvo, L., Bonetti, A., Seles, E., Giacobino, A., Chavarri Guerra, Y., de Jongh, F., van der Velden, A., van Warmerdam, L., Vrijaldenhoven, S., Smorenburg, C.H., Cavero, M., Andres Conejero, R., Oltra Ferrando, A., Redondo Sanchez, A., Ribelles Entrena, N., Saura Grau, S., Viñas Vilaro, G., Bachmeier, K., Beresford, M., Butt, M., Joffe, J., Poole, C., Woodings, P., Chakraborti, P., Yordi, G., Woodward, N., Nobre, A., Luiz Amorim, G., Califaretti, N., Fox, S., Robidoux, A., Li, E., Li, N., Jiang, J., Soria, T., Padrik, P., Lahdenpera, O., Barletta, H., Dohollou, N., Genet, D., Prulhiere, K., Coeffic, D., Facchini, T., Vieillot, S., Catala, S., Teixeira, L., Hesse, T., Kühn, T., Ober, A., Repp, R., Schröder, W., Pectasides, D., Bodoky, G., Kahan, Z., Jiveliouk, I., Rosengarten, O., Rossi, V., Alabiso, O., Pérez Martínez, M., van de Wouw, A.J., Smok-Kalwat, J., Damasecno, M., Augusto, I., Sousa, G., Saadein, A., Abdelhafiez, N., Abulkhair, O., Antón Torres, A., Corbellas Aparicio, M., Llorente Domenech, R., Florián Jerico, J., Garcia Mata, J., Gil Raga, M., Galan Brotons, A., Llombart Cussac, A., Llorca Ferrandiz, C., Martinez Del Prado, P., Olier Garate, C., Rodriguez Sanchez, C., Sanchez Gomez, R., Santisteban Eslava, M., Soberino, J., Vidal Losada Garcia, M., Soto de Prado, D., Torrego Garcia, J., Vicente Rubio, E., Garcia, M., Murias Rosales, A., Granstam Björneklett, H., Narbe, U., Jafri, M., Rea, D., Newby, J., Jones, A., Westwell, S., Ring, A., Alonso, I., Rodríguez, R., Ciruelos, E., Peretz-Yablonski, T., Merot, J.-L., Trask, P., du Toit, Y., Pena-Murillo, C., Revelant, V., and Klingbiel, D.

Published
2021
Full Text
View/download PDF

3. OA02.03 Amivantamab Plus Lazertinib vs Osimertinib in First-line EGFR-mutant Advanced NSCLC: Longer Follow-up of the MARIPOSA Study

Author

Gadgeel, S., Cho, B.C., Lu, S., Felip, E., Hayashi, H., Spira, A.I., Besse, B., Thomas, M., Owen, S., Kim, Y.J., Lee, S.-H., Mourão Dias, J., Lee, Y.-G., Zhao, Y., Fang, Y., Girard, N., Liu, Z., Sun, P., Oliveira, S.C. Sousa, Shen, H., Paz-Ares, L., Matsumoto, S., Tanaka, H., Ahmad, A.R., Andabekov, T., Sunpaweravong, P., Ozyilkan, O., Yang, J.C.-H., Gottfried, M., Hernandez, O., Kimmich, M., Cortinovis, D., Kaen, D.L., Montes, L.V. García, Popat, S., Newsom-Davis, T., Xie, J., Sun, T., Fennema, E., Daksh, M., Ennis, M., Sethi, S., Bauml, J.M., and Nguyen, D.

Published
2024
Full Text
View/download PDF

4. 908P Association of biomarkers with response to first-line (1L) vibostolimab (anti-TIGIT) coformulated with pembrolizumab (vibo/pembro) in advanced head and neck squamous cell carcinoma (HNSCC): Results from KEYVIBE-005

Author

Seo, S., Calderon, B., Chou, H-H., Hsu, C-H., Salman, P., Ghiringhelli, F., Ozyilkan, O., Rojas, C.I., Sendur, M.A.N., Le Tourneau, C., Yen, C.J., Shapira-Frommer, R., Rha, S.Y., Zhang, Y., Chen, C., Pena, C.E., Keenan, T., Chen, Y., Dettman, E., and Robinson, A.G.

Published
2024
Full Text
View/download PDF

5. 855P Safety and efficacy of vibostolimab (anti-TIGIT) coformulated with pembrolizumab (vibo/pembro) in previously untreated advanced head and neck squamous cell carcinoma (HNSCC): Results from the phase II KEYVIBE-005 study

Author

Toullec, C., Seo, S., Robinson, A.G., Chou, H-H., Salman, P., Ghiringhelli, F., Ozyilkan, O., Rojas, C.I., Sendur, M.A.N., Le Tourneau, C., Yen, C.J., Aksoy, S., Ochsenreither, S., Yanez Ruiz, E.P., Rha, S.Y., Shapira-Frommer, R., Liu, Q., Du Plessis, M., Keenan, T., and Hsu, C-H.

Published
2024
Full Text
View/download PDF

7. Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication

Author

Miles, D., primary, Ciruelos, E., additional, Schneeweiss, A., additional, Puglisi, F., additional, Peretz-Yablonski, T., additional, Campone, M., additional, Bondarenko, I., additional, Nowecki, Z., additional, Errihani, H., additional, Paluch-Shimon, S., additional, Wardley, A., additional, Merot, J.-L., additional, Trask, P., additional, du Toit, Y., additional, Pena-Murillo, C., additional, Revelant, V., additional, Klingbiel, D., additional, Bachelot, T., additional, Bouzid, K., additional, Desmoulins, I., additional, Coudert, B., additional, Glogowska, I., additional, Ciruelos Gil, E., additional, Dalenc, F., additional, Ricci, F., additional, Dieras, V., additional, Kaufman, B., additional, Ferreira, A., additional, Mano, M., additional, Kalofonos, H., additional, Andreetta, C., additional, Montemurro, F., additional, Barrett, S., additional, Zhang, Q., additional, Mavroudis, D., additional, Matus, J., additional, Villarreal Garza, C., additional, Beato, C., additional, Ismael, G., additional, Hu, X., additional, Abdel Azeem, H., additional, Gaafar, R., additional, Perrin, C., additional, Kerbrat, P., additional, Ettl, J., additional, Paepke, S., additional, Hitre, E., additional, Lang, I., additional, Trudeau, M., additional, Verma, S., additional, Li, H., additional, Hoffmann, O., additional, Aktas, B., additional, Cariello, A., additional, Cruciani, G., additional, Tienghi, A., additional, Tondini, C., additional, Al-Twegieri, T., additional, Loman, N., additional, Laing, R., additional, Miles, D., additional, Brain, E., additional, Fasching, P., additional, Lux, M., additional, Frassoldati, A., additional, Aziz, Z., additional, Salas, J., additional, Streb, J., additional, Krzemieniecki, K., additional, Wronski, A., additional, Garcia Garcia, J., additional, Menjon Beltran, S., additional, Cicin, I., additional, Schmid, P., additional, Gallagher, C., additional, Turner, N., additional, Tong, Z., additional, Boer, K., additional, Juhász, B., additional, Horvath, Z., additional, Bianchini, G., additional, Gianni, L., additional, Curigliano, G., additional, Juarez Ramiro, A., additional, Susnjar, S., additional, Matos, E., additional, Sevillano, E., additional, Garcia Estevez, L., additional, Gokmen, E., additional, Uslu, R., additional, Wildiers, H., additional, Schutz, F., additional, Cruz, M., additional, Bourgeois, H., additional, von Schumann, R., additional, Stemmer, S., additional, Dominguez, A., additional, Morales-Vásques, F., additional, Wojtukiewicz, M., additional, Trifunovic, J., additional, Echarri Gonzalez, M.J., additional, Illarramendi Mañas, J., additional, Martinez De Dueñas, E., additional, Voitko, N., additional, Hicks, J., additional, Waters, S., additional, Barrett-Lee, P., additional, Wheatley, D., additional, De Boer, R., additional, Cocquyt, V., additional, Jerusalem, G., additional, Barrios, C., additional, Panasci, L., additional, Mattson, J., additional, Tanner, M., additional, Gozy, M., additional, Vasilopoulos, G., additional, Papandreou, C., additional, Revesz, J., additional, Battelli, N., additional, Benedetti, G., additional, Latini, L., additional, Gridelli, C., additional, Lazaro Leon, J., additional, Alarcón Company, J., additional, Arance Fernandez, A., additional, Barnadas Molins, A., additional, Calvo Plaza, I., additional, Bratos, R., additional, Gonzalez Martin, A., additional, Izarzugaza Peron, Y., additional, Klint, L., additional, Kovalev, A., additional, McCarthy, N., additional, Yeo, B., additional, Kee, D., additional, Thomson, J., additional, White, S., additional, Greil, R., additional, Wang, S., additional, Artignan, X., additional, Juhasz-Böess, I., additional, Rody, A., additional, Ngan, R., additional, Dourleshter, F., additional, Goldberg, H., additional, Doni, L., additional, Di Costanzo, F., additional, Ferraù, F., additional, Drobniene, M., additional, Aleknavicius, E., additional, Rashid, K., additional, Costa, L., additional, de la Cruz Merino, L., additional, Garcia Saenz, J., additional, López, R., additional, Del Val Munoz, O., additional, Ozyilkan, O., additional, Azribi, F., additional, Jaafar, H., additional, Baird, R., additional, Verrill, M., additional, Beith, J., additional, Petzer, A., additional, Moreira de Andrade, J., additional, Bernstein, V., additional, Macpherson, N., additional, Rayson, D., additional, Saad Eldin, I., additional, Achille, M., additional, Augereau, P., additional, Müller, V., additional, Rasco, A., additional, Evron, E., additional, Katz, D., additional, Berardi, R., additional, Cascinu, S., additional, De Censi, A., additional, Gennari, A., additional, El-Saghir, N., additional, Ghosn, M., additional, Oosterkamp, H.M., additional, Van den Bosch, J., additional, Kukulska, M., additional, Kalinka, E., additional, Alonso, J., additional, Dalmau Portulas, E., additional, Del Mar Gordon Santiago, M., additional, Pelaez Fernandez, I., additional, Aksoy, S., additional, Altundag, K., additional, Senol Coskun, H., additional, Bozcuk, H., additional, Shparyk, Y., additional, Barraclough, L., additional, Levitt, N., additional, Panwar, U., additional, Kelly, S., additional, Rigg, A., additional, Varughese, M., additional, Castillo, C., additional, Fein, L., additional, Malik, L., additional, Stuart-Harris, R., additional, Singer, C., additional, Stoeger, H., additional, Samonigg, H., additional, Feng, J., additional, Cedeño, M., additional, Ruohola, J., additional, Berdah, J.-F., additional, Goncalves, A., additional, Orfeuvre, H., additional, Grischke, E.-M., additional, Simon, E., additional, Wagner, S., additional, Koumakis, G., additional, Papazisis, K., additional, Ben Baruch, N., additional, Fried, G., additional, Geffen, D., additional, Karminsky, N., additional, Peretz, T., additional, Cavanna, L., additional, Pedrazzioli, P., additional, Grasso, D., additional, Ruggeri, E., additional, D’Auria, G., additional, Moscetti, L., additional, Juozaityte, E., additional, Rodriguez Cid, J., additional, Roerdink, H., additional, Siddiqi, N., additional, Passos Coelho, J., additional, Arcediano Del Amo, A., additional, Garcia Garre, E., additional, García Gonzalez, M., additional, Garcia-Palomo Perez, A., additional, Herenandez Perez, C., additional, Lopez Alvarez, P., additional, Lopez De Ceballos, M.H., additional, Martínez Jañez, N., additional, Mele Olive, M., additional, McAdam, K., additional, Perren, T., additional, Dunn, G., additional, Humphreys, A., additional, Taylor, W., additional, Vera, R., additional, Kaen, L., additional, Andel, J., additional, Steger, G., additional, De Grève, J., additional, Huizing, M., additional, Hegg, R., additional, Joy, A., additional, Kuruvilla, P., additional, Sehdev, S., additional, Smiljanic, S., additional, Kütner, R., additional, Alexandre, J., additional, Grosjean, J., additional, Laplaige, P., additional, Largillier, R., additional, Maes, P., additional, Martin, P., additional, Pottier, V., additional, Christensen, B., additional, Khandan, F., additional, Lück, H.-J., additional, Zahm, D.-M., additional, Fountzilas, G., additional, Karavasilis, V., additional, Safra, T., additional, Inbar, M., additional, Ryvo, L., additional, Bonetti, A., additional, Seles, E., additional, Giacobino, A., additional, Chavarri Guerra, Y., additional, de Jongh, F., additional, van der Velden, A., additional, van Warmerdam, L., additional, Vrijaldenhoven, S., additional, Smorenburg, C.H., additional, Cavero, M., additional, Andres Conejero, R., additional, Oltra Ferrando, A., additional, Redondo Sanchez, A., additional, Ribelles Entrena, N., additional, Saura Grau, S., additional, Viñas Vilaro, G., additional, Bachmeier, K., additional, Beresford, M., additional, Butt, M., additional, Joffe, J., additional, Poole, C., additional, Woodings, P., additional, Chakraborti, P., additional, Yordi, G., additional, Woodward, N., additional, Nobre, A., additional, Luiz Amorim, G., additional, Califaretti, N., additional, Fox, S., additional, Robidoux, A., additional, Li, E., additional, Li, N., additional, Jiang, J., additional, Soria, T., additional, Padrik, P., additional, Lahdenpera, O., additional, Barletta, H., additional, Dohollou, N., additional, Genet, D., additional, Prulhiere, K., additional, Coeffic, D., additional, Facchini, T., additional, Vieillot, S., additional, Catala, S., additional, Teixeira, L., additional, Hesse, T., additional, Kühn, T., additional, Ober, A., additional, Repp, R., additional, Schröder, W., additional, Pectasides, D., additional, Bodoky, G., additional, Kahan, Z., additional, Jiveliouk, I., additional, Rosengarten, O., additional, Rossi, V., additional, Alabiso, O., additional, Pérez Martínez, M., additional, van de Wouw, A.J., additional, Smok-Kalwat, J., additional, Damasecno, M., additional, Augusto, I., additional, Sousa, G., additional, Saadein, A., additional, Abdelhafiez, N., additional, Abulkhair, O., additional, Antón Torres, A., additional, Corbellas Aparicio, M., additional, Llorente Domenech, R., additional, Florián Jerico, J., additional, Garcia Mata, J., additional, Gil Raga, M., additional, Galan Brotons, A., additional, Llombart Cussac, A., additional, Llorca Ferrandiz, C., additional, Martinez Del Prado, P., additional, Olier Garate, C., additional, Rodriguez Sanchez, C., additional, Sanchez Gomez, R., additional, Santisteban Eslava, M., additional, Soberino, J., additional, Vidal Losada Garcia, M., additional, Soto de Prado, D., additional, Torrego Garcia, J., additional, Vicente Rubio, E., additional, Garcia, M., additional, Murias Rosales, A., additional, Granstam Björneklett, H., additional, Narbe, U., additional, Jafri, M., additional, Rea, D., additional, Newby, J., additional, Jones, A., additional, Westwell, S., additional, Ring, A., additional, Alonso, I., additional, and Rodríguez, R., additional

Published
2021
Full Text
View/download PDF

8. Palliative Care, and Oncologists (ARES Study): a Study of the Palliative

Author

Oktay, E, Levent, M, Gelincik, H, Aktas, G, Yumuk, F, Koral, L, Arpaci, E, Keser, M, Alkan, A, Karci, E, Karadurmus, N, Degirmencioglu, S, Turan, M, Uyeturk, U, Cabuk, D, Avci, N, Toprak, O, Ergen, A, Urvay, S, Bayman, E, Petekkaya, E, Nayir, E, Paydas, S, Yavuzsen, T, Senler, FC, Yaren, A, Barutca, S, Sahinler, I, Ozyilkan, O, and Tanriverdi, O

Subjects
Medicine students, Cancer, Palliative care, Oncologists
Abstract

Cancer is one of the most common causes of death all over the World (Rahib et al. in Cancer Res 74(11):2913-2921, 2014; Silbermann et al. in Ann Oncol 23(Suppl 3):iii15-iii28, 2012). It is crucial to diagnose this disease early by effective screening methods and also it is very important to acknowledge the community on various aspects of this disease such as the treatment methods and palliative care. Not only the oncologists but every medical doctor should be educated well in dealing with cancer patients. Previous studies suggested various opinions on the level of oncology education in medical schools (Pavlidis et al. in Ann Oncol 16(5):840-841, 2005). In this study, the perspectives of medical students on cancer, its treatment, palliative care, and the oncologists were analyzed in relation to their educational status. A multicenter survey analysis was performed on a total of 4224 medical school students that accepted to enter this study in Turkey. After the questions about the demographical characteristics of the students, their perspectives on the definition, diagnosis, screening, and treatment methods of cancer and their way of understanding metastatic disease as well as palliative care were analyzed. The questionnaire includes questions with answers and a scoring system of Likert type 5 (absolutely disagree = 1, completely agree = 5). In the last part of the questionnaire, there were some words to detect what the words "cancer" and "oncologist" meant for the students. The participant students were analyzed in two study groups; "group 1" (n = 1.255) were phases I and II students that had never attended an oncology lesson, and "group 2" (n = 2.969) were phases III to VI students that had attended oncology lessons in the medical school. SPSS v17 was used for the database and statistical analyses. A value of p < 0.05 was noted as statistically significant. Group 1 defined cancer as a contagious disease (p = 0.00025), they believed that early diagnosis was never possible (p = 0.042), all people with a diagnosis of cancer would certainly die (p = 0.044), and chemotherapy was not successful in a metastatic disease (p = 0.003) as compared to group 2. The rate of the students that believed gastric cancer screening was a part of the national screening policy was significantly more in group 1 than in group 2 (p = 0.00014). Group 2 had a higher anxiety level for themselves or their family members to become a cancer patient. Most of the students in both groups defined medical oncologists as warriors (57% in group 1 and 40% in group 2; p = 0.097), and cancer was reminding them of "death" (54% in group 1 and 48% in group 2; p = 0.102). This study suggested that oncology education was useful for the students' understanding of cancer and related issues; however, the level of oncology education should be improved in medical schools in Turkey. This would be helpful for medical doctors to cope with many aspects of cancer as a major health care problem in this country. C1 [Oktay, Esin; Turan, Merve; Barutca, Sabri] Adnan Menderes Univ, Dept Med Oncol, Fac Med, Aydin, Turkey. [Levent, Mustafa] Sitki Kocman Univ, Dept Internal Med, Fac Med, Mugla, Turkey. [Gelincik, Hakan; Aktas, Gizem; Paydas, Semra] Cukurova Univ, Dept Med Oncol, Fac Med, Adana, Turkey. [Yumuk, Fulden] Marmara Univ, Dept Med Oncol, Fac Med, Istanbul, Turkey. [Koral, Lokman] Onsekiz Mart Univ, Dept Med Oncol, Fac Med, Canakkale, Turkey. [Arpaci, Erkan] Sakarya Univ, Dept Med Oncol, Fac Med, Sakarya, Turkey. [Keser, Murat; Yavuzsen, Tugba] Dokuz Eylul Univ, Dept Med Oncolog, Fac Med, Izmir, Turkey. [Alkan, Ali; Senler, Filiz Cay] Ankara Univ, Dept Med Oncol, Fac Med, Ankara, Turkey. [Karci, Ebru; Karadurmus, Nuri] Gulhane Mil Med Acad, Dept Med Oncol, Ankara, Turkey. [Degirmencioglu, Serkan; Yaren, Arzu] Pamukkale Univ, Dept Med Oncol, Fac Med, Denizli, Turkey. [Uyeturk, Ummugul] Abant Izzet Baysal Univ, Dept Med Oncol, Fac Med, Bolu, Turkey. [Cabuk, Devrim] Kocaeli Univ, Dept Med Oncol, Fac Med, Izmit, Turkey. [Avci, Nilufer] Balikesir Univ, Dept Med Oncol, Fac Med, Balikesir, Turkey. [Toprak, Omer] Balikesir Univ, Dept Internal Med, Fac Med, Balikesir, Turkey. [Ergen, Arzu; Sahinler, Ismet] Istanbul Univ, Cerrahpasa Fac Med, Dept Radiat Oncol, Istanbul, Turkey. [Urvay, Semiha] Cumhuriyet Univ, Dept Med Oncol, Fac Med, Sivas, Turkey. [Bayman, Evrim] Osmangazi Univ, Dept Radiat Oncol, Fac Med, Eskisehir, Turkey. [Petekkaya, Emine] Beykent Univ, Dept Anat, Fac Med, Istanbul, Turkey. [Nayir, Erdinc] Mersin Medicalpark Hosp, Dept Med Oncol, Mersin, Turkey. [Ozyilkan, Ozgur] Baskent Univ, Dept Med Oncol, Fac Med, Ankara, Turkey. [Tanriverdi, Ozgur] Mugla Sitki Kocman Univ, Fac Med, Dept Med Oncol, Mugla, Turkey.

Published
2020

9. 273O nextMONARCH: Final overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with HR+, HER2- metastatic breast cancer

Author

Hamilton, E.P., primary, Cortés, J., additional, Ozyilkan, O., additional, Chen, S-C., additional, Petrakova, K., additional, Manikhas, A., additional, Jerusalem, G., additional, Hegg, R., additional, Huober, J., additional, Chapman, S.C., additional, Yang, Z., additional, Chen, Y., additional, Johnston, E.L., additional, and Martin, M., additional

Published
2020
Full Text
View/download PDF

11. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

Author

Burtness, B. Harrington, K.J. Greil, R. Soulières, D. Tahara, M. de Castro, G., Jr Psyrri, A. Basté, N. Neupane, P. Bratland, Å. Fuereder, T. Hughes, B.G.M. Mesía, R. Ngamphaiboon, N. Rordorf, T. Wan Ishak, W.Z. Hong, R.-L. González Mendoza, R. Roy, A. Zhang, Y. Gumuscu, B. Cheng, J.D. Jin, F. Rischin, D. Lerzo, G. Tatangelo, M. Varela, M. Zarba, J.J. Boyer, M. Gan, H. Gao, B. Hughes, B. Mallesara, G. Taylor, A. Burian, M. Barrios, C.H. de Castro Junior, D.O. Castro, G. Franke, F.A. Girotto, G. Lima, I.P.F. Nicolau, U.R. Pinto, G.D.J. Santos, L. Victorino, A.-P. Chua, N. Couture, F. Gregg, R. Hansen, A. Hilton, J. McCarthy, J. Soulieres, D. Ascui, R. Gonzalez, P. Villanueva, L. Torregroza, M. Zambrano, A. Holeckova, P. Kral, Z. Melichar, B. Prausova, J. Vosmik, M. Andersen, M. Gyldenkerne, N. Jurgens, H. Putnik, K. Reinikainen, P. Gruenwald, V. Laban, S. Aravantinos, G. Boukovinas, I. Georgoulias, V. Kwong, D. Al-Farhat, Y. Csoszi, T. Erfan, J. Horvai, G. Landherr, L. Remenar, E. Ruzsa, A. Szota, J. Billan, S. Gluck, I. Gutfeld, O. Popovtzer, A. Benasso, M. Bui, S. Ferrari, V. Licitra, L. Nole, F. Fujii, T. Fujimoto, Y. Hanai, N. Hara, H. Matsumoto, K. Mitsugi, K. Monden, N. Nakayama, M. Okami, K. Oridate, N. Shiga, K. Shimizu, Y. Sugasawa, M. Takahashi, M. Takahashi, S. Tanaka, K. Ueda, T. Yamaguchi, H. Yamazaki, T. Yasumatsu, R. Yokota, T. Yoshizaki, T. Kudaba, I. Stara, Z. Cheah, S.K. Aguilar Ponce, J. Gonzalez Mendoza, R. Hernandez Hernandez, C. Medina Soto, F. Buter, J. Hoeben, A. Oosting, S. Suijkerbuijk, K. Bratland, A. Brydoey, M. Alvarez, R. Mas, L. Caguioa, P. Querol, J. Regala, E.E. Tamayo, M.B. Villegas, E.M. Kawecki, A. Karpenko, A. Klochikhin, A. Smolin, A. Zarubenkov, O. Goh, B.C. Cohen, G. du Toit, J. Jordaan, C. Landers, G. Ruff, P. Szpak, W. Tabane, N. Brana, I. Iglesias Docampo, L. Lavernia, J. Mesia, R. Abel, E. Muratidu, V. Nielsen, N. Cristina, V. Rothschild, S. Wang, H.-M. Yang, M.-H. Yeh, S.-P. Yen, C.-J. Soparattanapaisarn, N. Sriuranpong, V. Aksoy, S. Cicin, I. Ekenel, M. Harputluoglu, H. Ozyilkan, O. Agarwala, S. Ali, H. Alter, R. Anderson, D. Bruce, J. Campbell, N. Conde, M. Deeken, J. Edenfield, W. Feldman, L. Gaughan, E. Goueli, B. Halmos, B. Hegde, U. Hunis, B. Jotte, R. Karnad, A. Khan, S. Laudi, N. Laux, D. Martincic, D. McCune, S. McGaughey, D. Misiukiewicz, K. Mulford, D. Nadler, E. Nunnink, J. Ohr, J. O'Malley, M. Patson, B. Paul, D. Popa, E. Powell, S. Redman, R. Rella, V. Rocha Lima, C. Sivapiragasam, A. Su, Y. Sukari, A. Wong, S. Yilmaz, E. Yorio, J.

Abstract

Background: Pembrolizumab is active in head and neck squamous cell carcinoma (HNSCC), with programmed cell death ligand 1 (PD-L1) expression associated with improved response. Methods: KEYNOTE-048 was a randomised, phase 3 study of participants with untreated locally incurable recurrent or metastatic HNSCC done at 200 sites in 37 countries. Participants were stratified by PD-L1 expression, p16 status, and performance status and randomly allocated (1:1:1) to pembrolizumab alone, pembrolizumab plus a platinum and 5-fluorouracil (pembrolizumab with chemotherapy), or cetuximab plus a platinum and 5-fluorouracil (cetuximab with chemotherapy). Investigators and participants were aware of treatment assignment. Investigators, participants, and representatives of the sponsor were masked to the PD-L1 combined positive score (CPS) results; PD-L1 positivity was not required for study entry. The primary endpoints were overall survival (time from randomisation to death from any cause) and progression-free survival (time from randomisation to radiographically confirmed disease progression or death from any cause, whichever came first) in the intention-to-treat population (all participants randomly allocated to a treatment group). There were 14 primary hypotheses: superiority of pembrolizumab alone and of pembrolizumab with chemotherapy versus cetuximab with chemotherapy for overall survival and progression-free survival in the PD-L1 CPS of 20 or more, CPS of 1 or more, and total populations and non-inferiority (non-inferiority margin: 1·2) of pembrolizumab alone and pembrolizumab with chemotherapy versus cetuximab with chemotherapy for overall survival in the total population. The definitive findings for each hypothesis were obtained when statistical testing was completed for that hypothesis; this occurred at the second interim analysis for 11 hypotheses and at final analysis for three hypotheses. Safety was assessed in the as-treated population (all participants who received at least one dose of allocated treatment). This study is registered at ClinicalTrials.gov, number NCT02358031. Findings: Between April 20, 2015, and Jan 17, 2017, 882 participants were allocated to receive pembrolizumab alone (n=301), pembrolizumab with chemotherapy (n=281), or cetuximab with chemotherapy (n=300); of these, 754 (85%) had CPS of 1 or more and 381 (43%) had CPS of 20 or more. At the second interim analysis, pembrolizumab alone improved overall survival versus cetuximab with chemotherapy in the CPS of 20 or more population (median 14·9 months vs 10·7 months, hazard ratio [HR] 0·61 [95% CI 0·45–0·83], p=0·0007) and CPS of 1 or more population (12·3 vs 10·3, 0·78 [0·64–0·96], p=0·0086) and was non-inferior in the total population (11·6 vs 10·7, 0·85 [0·71–1·03]). Pembrolizumab with chemotherapy improved overall survival versus cetuximab with chemotherapy in the total population (13·0 months vs 10·7 months, HR 0·77 [95% CI 0·63–0·93], p=0·0034) at the second interim analysis and in the CPS of 20 or more population (14·7 vs 11·0, 0·60 [0·45–0·82], p=0·0004) and CPS of 1 or more population (13·6 vs 10·4, 0·65 [0·53–0·80], p

Published
2019

12. Miscellaneous I

Author

Bòveda T, J. L., Ruiz R, J. C., de Latorre A, F. J., Gonzalez A, M. T., Boye P, R., Monasterio A, J., Allaouchiche, B., Bernard, C., Nedey, C., Sabben, F., Ganichot, F., Marti-Flich, J., Combourieu, E., Patrigeon, R. G., Mignot, F., Palmier, B., Estecha, M. A., Romera, M. A., Nieto, M., Molina, J. M., Rubio, J. J., Torrecilla, C., Durocher, A., Cadelis, G., Saulnier, F., Herengt, F., Wattel, F., Asmussen, J., Gellett, S., Pilegaard, H., Gottrup, F., West, I. P., Griffiths, R. G., Holmes, R., Snowdon, S. L., Jones, G. R., Clutton-Brock, T. H., Hendry, S. P., Fink, S., Cook, D. J., Veligotsky, A. N., Tarasov, V. F., Sheremet, A. I., Volkova, N. A., Ozyilkan, E., Ozyilkan, O., Korkmaz, M. E., Kayhan, B., Bayraktar, Y., Karaagaoglu, E., Asian, S., Telatar, H., Rabanal, J. M., Amado, J. A., Quesada, A., López-Espadas, F., Regañón, G., Forns, X., Salmerón, J. M., Mas, A., Valderrama, E., Cabal, G., Rimola, A., Rodés, J., Evrard, P., Dive, A., Gonzalez, M., Delaunois, L., Schoevaerdts, J. C., Installé, E., Sollazzi, L., Perilli, V., Avolio, A. W., Agnes, S., Morelli, G., Bozza, P., Modesti, C., Bradariolo, S., Castagneto, M., Wolf, Ch. -F., Brinkmann, A., Meyerhoff, C., Grünert, A., Keck, F. S., Guidet, B., Staikowsky, F., Vassal, T., Offenstadt, G., and Amstutz, P.

Published
1992
Full Text
View/download PDF

17. P1.14-15 Lorlatinib in ALK- or ROS1-Positive Non-Small Cell Lung Cancer Patients: Experience from an Early Access Program in Turkey

Author

Kilickap, S., primary, Demirci, U., additional, Bugdayci, F., additional, Tural, D., additional, Korkmaz, T., additional, Paydas, S., additional, Yilmaz, C., additional, Turna, H., additional, Sezer, A., additional, Cinkir, H. Yesil, additional, Okutur, K., additional, Erman, M., additional, Eralp, Y., additional, Cabuk, D., additional, Isikdogan, A., additional, Demirkazik, A., additional, Karaoglu, A., additional, Yazilitas, D., additional, Senler, F. Cay, additional, Yumuk, P.F., additional, Coskun, H., additional, Yildiz, I., additional, Oztop, I., additional, Beypinar, I., additional, Aydin, K., additional, Kaplan, M., additional, Meydan, N., additional, Olmez, O.F., additional, Ozyilkan, O., additional, Seber, S., additional, Arslan, C., additional, Sendur, M.A., additional, and Cicin, I., additional

Published
2019
Full Text
View/download PDF

20. registry study (A Turkish Oncology Group trial)

Author

Aykan, NF, Yalcin, S, Turhal, NS, Ozdogan, M, Demir, G, Ozkan, M, Yaren, A, Camci, C, Akbulut, H, Artac, M, Meydan, N, Uygun, K, Isikdogan, A, Unsal, D, Ozyilkan, O, Arican, A, Seyrek, E, Tekin, SB, Manavoglu, O, Ozet, A, Elkiran, T, and Disci, R

Subjects
Colorectal cancer, epidemiology, risk factors, Turkey
Abstract

Background/Aims: This study aimed to determine the epidemiological characteristics of colorectal cancer in Turkey. Materials and Methods: In this multicenter, prospective, and cross-sectional registry study, data for 968 patients with colorectal cancer from 21 centers in 7 geographic regions were analyzed. Results: Diagnosis was colon cancer in 662 (68.4%) and rectum cancer in 306 (31.6%) patients. In total, 60.9% of patients was male; mean age was 58.9 +/- 12.6 years. Among patients, 15.0% was drinking alcohol, 17.5% was smoking, 1.5% had familial history of polyposis, 15.0% had diabetes mellitus, 1.0% had inflammatory bowel disease. Fruit and vegetable consumption was low (= 3 times/week) in 47.4% of the patients. Median time-to diagnosis was 3.0 months and 4.0 months for patients with colon and rectum cancer, respectively. Mean body mass index was >25 in all group of patients. Distal rectum (61.3%) and sigmoid colon (36.8%) were the most common locations of cancer, for rectum and colon respectively. In total, 85.6% of patients were operated; 25.8% had emergency surgery. Low anterior resection rate was 64.2% in rectum cancer. In majority (89.8%) of the patients with rectum cancer who received preoperative treatment, conventional chemo-radiotherapy regimen was given. pTNM staging at diagnosis showed that stage III and IV patients were in majority (35.9% and 29.7%, respectively). Conclusion: Colon cancer is more frequent than rectum cancer in Turkey. Colorectal cancer patients are diagnosed at later stages. Most of the cases were operated. Interregional differences for risk factors are worthwhile for evaluation in future trials.

Published
2015

21. The Perspective of Non-oncologist Physicians on Patients with Metastatic

Author

Tanriverdi, O, Yavuzsen, T, Akman, T, Senler, FC, Taskoylu, BY, Turhal, S, Komurcu, S, Cehreli, R, Yaren, A, and Ozyilkan, O

Subjects
Physicians, Palliative care, Best supportive care, Cancer, Metastatic, disease, Terminal stage cancer
Abstract

The aim of our study was to determine the perspective of non-oncologist physicians regarding their attitudes and beliefs associated with palliative care for patients with metastatic cancer. The study was planned as a cross-sectional survey, and non-oncologist physicians were reached via e-mail and social networking sites. The first part of the questionnaire involved demographic properties, the second part inquired as to the perspectives of participants regarding metastatic disease, and the third part was used to determine beliefs and attitudes about palliative care. All of the questions were five-point Likert-type questions. A total of 1734 physicians completed the questionnaire. The majority of participants were general surgeons or internal medicine specialists (21 and 18 %, respectively), were male (61 %), were younger than 50 years of age (54 %), worked in the town center (67 %), had more than 11 years of professional experience (57 %), and worked in a hospital without an active oncology service (86 %). A total of 71 % of participants identified all patients with metastatic cancer as being terminal stage, 62 % were unaware of palliative care techniques, 64 % did not know about common supportive care options, 59 % were against hospice, and 63 % had no opinion on resuscitation. We determined that non-oncologist physicians believed that all patients with metastatic cancer are at the terminal stage and that palliative/supportive care is the oncologist's task. These data suggest that non-oncologist physicians would benefit from additional graduate and postgraduate courses on these topics.

Published
2015

40. Outcomes of hepatocellular carcinoma

Author

Yildirim, Y., primary, Ozyilkan, O., additional, Akcali, Z., additional, Remzi, E., additional, Sevmis, S., additional, Demirhan, B., additional, Bilezikci, B., additional, Karakayali, H., additional, and Haberal, M., additional

Published
2006
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results